Genmab As (OTCMKTS:GNMSF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, January 9th.
According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “
Separately, JPMorgan Chase & Co. downgraded Genmab As from an “overweight” rating to a “neutral” rating in a report on Friday, October 6th.
About Genmab As
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genmab As Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab As and related companies with MarketBeat.com's FREE daily email newsletter.